Dual targeting of PD-L1 and integrin for preclinical PET imaging of cancers

Molecular imaging is significant to personalized and precision medicine. Although singly targeted imaging probes are making a substantial impact both clinically and preclinically, molecular imaging strategies using bispecific probes have enabled improved visualization of cancer in recent years through synergistic targeting of two ligands.1 Dual targeting strategy can improve the imaging contrast by enhancing the specific uptake. Immune checkpoint PD-L1 is a prominent biomarker for patient selection in immune checkpoint therapy. Here, we aim to develop a bispecific probe for tumor imaging by combining an integrin-targeting peptide cycloRGD and a PD-L1-targeting peptide TPP-12.第59回日本核医学会学術総